Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients

Documenti analoghi

• Real‐World Off‐Label Use of Letermovir Prophylaxis for Cytomegalovirus Prevention in Non‐Kidney Solid Organ Transplant Recipients: Outcomes, Safety, and Review of Literature
  di: Abdallah Mughrabi, et al.
  Pubblicazione: (2026)
• Hepatitis B Vaccine Compliance, Serologic Response, and Durability in Adult Thoracic Organ Transplant Recipients
  di: Chia‐Yu Chiu, et al.
  Pubblicazione: (2024)
• Posttransplant HBV Vaccine Compliance, Seroprotection, and Kinetics of Hepatitis B Surface Antibody in Thoracic Organ Transplant Recipients
  di: Chia‐Yu Chiu, et al.
  Pubblicazione: (2025)
• Survey of Post‐Prophylaxis Delayed‐Onset Cytomegalovirus Management Strategies Among Transplant Providers
  di: Lemuel R. Non, et al.
  Pubblicazione: (2024)
• Discordance in serology for cytomegalovirus, Epstein‐Barr virus and toxoplasma among thoracic organ donors
  di: Chia‐Yu Chiu, et al.
  Pubblicazione: (2024)